BTK Inhibitors in CLL/SLL and MCL

CE / CME

Key Considerations for the Individualizing Use of BTK Inhibitors in B-Cell Malignancies

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: October 11, 2023

Expiration: October 10, 2024

Matthew S Davids
Matthew S Davids, MD, MMSc
Josie Montegaard
Josie Montegaard, MSN, AGPCNP-BC

Pretest

Progress
1 2
Course Completed
Please answer the questions below.
1.

Which of the following Bruton’s tyrosine kinase (BTK) inhibitors has demonstrated high activity in patients with chronic lymphocytic leukemia (CLL) and progression on another BTK inhibitor?

2.

Which of the following adverse events is NOT common among all FDA-approved BTK inhibitors?

3.

Which of the following cytogenetic markers is a hallmark of mantle cell lymphoma (MCL)?

4.

BTK has an important role in all the following cellular processes EXCEPT:

5.

Which of the following is an approved noncovalent BTK inhibitor for the management of relapsed/refractory MCL?

6.

Which of the following markers is most important to assess to guide treatment decisions for patients with CLL based on current guidelines and expert recommendations?

7.

Which of the following would you recommend for a patient with newly diagnosed unmutated IGHV CLL and del(17p), without a TP53 mutation?

8.

In your current clinical practice, which of the following patient characteristics may lead you to consider acalabrutinib over zanubrutinib for a patient with CLL?

9.

For a patient with R/R MCL receiving a second-line BTK inhibitor who is scheduled to have tooth extraction, which of the following strategies is recommended to manage his bleeding risk?

10.

How often do you currently consider patient comorbidities when recommending specific BTK inhibitors for your patients with CLL/SLL or MCL?